|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
260,040,000 |
Market
Cap: |
115.21(B) |
Last
Volume: |
975,365 |
Avg
Vol: |
1,608,800 |
52
Week Range: |
$323.62 - $456.95 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 543 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
23,137 |
144,475 |
259,873 |
619,971 |
Total Sell Value |
$10,319,530 |
$60,539,246 |
$102,205,755 |
$209,876,745 |
Total People Sold |
7 |
12 |
14 |
18 |
Total Sell Transactions |
7 |
40 |
65 |
130 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Silva Paul M |
SVP & Chief Accounting Officer |
|
2021-02-17 |
4 |
D |
$211.75 |
$580,195 |
D/D |
(2,740) |
21,123 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2021-02-17 |
4 |
D |
$211.75 |
$440,440 |
D/D |
(2,080) |
66,541 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2021-02-17 |
4 |
D |
$211.75 |
$423,500 |
D/D |
(2,000) |
32,468 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2021-02-17 |
4 |
D |
$211.75 |
$1,321,320 |
D/D |
(6,240) |
46,858 |
|
- |
|
Arbuckle Stuart A |
EVP, Chief Commercial Officer |
|
2021-02-17 |
4 |
D |
$211.75 |
$1,321,320 |
D/D |
(6,240) |
55,460 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2021-02-11 |
4 |
AS |
$210.44 |
$355,012 |
D/D |
(1,686) |
38,864 |
|
-11% |
|
Arbuckle Stuart A |
EVP, Chief Commercial Officer |
|
2021-02-11 |
4 |
AS |
$210.39 |
$1,085,593 |
D/D |
(5,156) |
61,700 |
|
-11% |
|
Sachdev Amit |
EVP, Chief Patient Officer |
|
2021-02-11 |
4 |
AS |
$210.43 |
$939,068 |
D/D |
(4,460) |
63,542 |
|
-11% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2021-02-11 |
4 |
AS |
$210.42 |
$1,112,274 |
D/D |
(5,283) |
53,098 |
|
-11% |
|
Parini Michael |
EVP, Chief Adm, Leg & BD Off |
|
2021-02-11 |
4 |
AS |
$210.43 |
$909,179 |
D/D |
(4,318) |
50,346 |
|
-11% |
|
Silva Paul M |
SVP & Chief Accounting Officer |
|
2021-02-11 |
4 |
AS |
$210.45 |
$315,437 |
D/D |
(1,498) |
23,863 |
|
-11% |
|
Leiden Jeffrey M |
Executive Chairman |
|
2021-02-10 |
4 |
D |
$214.16 |
$2,988,389 |
D/D |
(13,954) |
63,646 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2021-02-10 |
4 |
D |
$214.16 |
$636,912 |
D/D |
(2,974) |
58,381 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2021-02-10 |
4 |
D |
$214.16 |
$506,488 |
D/D |
(2,365) |
35,773 |
|
- |
|
Arbuckle Stuart A |
EVP, Chief Commercial Officer |
|
2021-02-10 |
4 |
D |
$214.16 |
$664,110 |
D/D |
(3,101) |
66,856 |
|
- |
|
Parini Michael |
EVP, Chief Adm, Leg & BD Off |
|
2021-02-10 |
4 |
D |
$214.16 |
$548,892 |
D/D |
(2,563) |
54,664 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2021-02-10 |
4 |
D |
$214.16 |
$287,831 |
D/D |
(1,344) |
40,550 |
|
- |
|
Silva Paul M |
SVP & Chief Accounting Officer |
|
2021-02-10 |
4 |
D |
$214.16 |
$139,418 |
D/D |
(651) |
25,361 |
|
- |
|
Kewalramani Reshma |
CEO & President |
|
2021-02-10 |
4 |
D |
$214.16 |
$634,342 |
D/D |
(2,962) |
68,621 |
|
- |
|
Sachdev Amit |
EVP, Chief Patient Officer |
|
2021-02-10 |
4 |
D |
$214.16 |
$518,481 |
D/D |
(2,421) |
68,002 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2021-02-10 |
4 |
D |
$214.16 |
$263,417 |
D/D |
(1,230) |
34,468 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2021-02-10 |
4 |
D |
$214.16 |
$506,917 |
D/D |
(2,367) |
33,575 |
|
- |
|
Parini Michael |
EVP, Chief Adm, Leg & BD Off |
|
2021-02-05 |
4 |
AS |
$215.00 |
$414,950 |
D/D |
(1,930) |
57,227 |
|
-13% |
|
Parini Michael |
EVP, Chief Adm, Leg & BD Off |
|
2021-02-05 |
4 |
OE |
$86.52 |
$166,984 |
D/D |
1,930 |
59,157 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic TherapiesO |
|
2021-02-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,175 |
|
-10% |
|
3277 Records found
|
|
Page 19 of 132 |
|
|